Atavistik Bio and Roche sign allosteric drug discovery collaboration worth up to $1.9bn
The collaboration gives Roche access to Atavistik Bio's AMPS platform to discover allosteric small molecules across cardiovascular, renal and metabolic disease targets.
Roche and Atavistik Bio have entered a multi-target research collaboration using Atavistik's AMPS platform to identify and develop allosteric small-molecule therapies.
Atavistik will receive $70 million upfront and could earn up to $1.9 billion in milestone payments, as well as tiered royalties on resulting products.
Field | Content |
Field | Content |
Alert Type | Research Collaboration |
Companies | Atavistik Bio; Roche |
Deal Type | Multi-target research collaboration |
Technology/Platform | AMPS allosteric drug discovery platform |
Therapy Areas | Cardiovascular, renal and metabolic diseases |
Technology/Modality | Allosteric small molecules |
Upfront Payment | $70 million |
Potential Milestones | Up to $1.9 billion |
Additional Economics | Tiered royalties |
What Happened | Roche entered a collaboration with Atavistik Bio to discover and develop allosteric small-molecule therapies against multiple targets. |
Why It Matters | The agreement pairs Roche's drug-development capabilities with Atavistik's platform for identifying allosteric binding opportunities. |
Strategic Rationale | The collaboration is designed to generate new medicines against cardiovascular, renal and metabolic disease targets. |
Potential Impact | Successful programmes could broaden Roche's pipeline while validating Atavistik's AMPS platform across multiple targets. |
Key Takeaway | The collaboration carries potential economics of nearly $2 billion in upfront and milestone payments before royalties. |
What to Watch | Target progression, candidate nominations and movement of programmes into clinical development. |
Primary Source | Atavistik Bio |
Relevant Date | 24 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários